Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes

Mahley, 1988, Apolipoprotein E: cholesterol transport protein with expanding role in cell biology, Science, 240, 622, 10.1126/science.3283935 Mahley, 1995, Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism, 1953 Mahley, 1999, Remnant lipoprotein metabolism: Key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E, J. Lipid Res., 40, 1, 10.1016/S0022-2275(20)33334-4 Mahley, 1998, Disorders of lipid metabolism, 1099 Mahley, 1999, Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond, Curr. Opin. Lipidol., 10, 207, 10.1097/00041433-199906000-00003 Schaefer, 1986, Familial apolipoprotein E deficiency, J. Clin. Invest., 78, 1206, 10.1172/JCI112704 Mabuchi, 1989, A young type III hyperlipoproteinemic patient associated with apolipoprotein E deficiency, Metabolism, 38, 115, 10.1016/0026-0495(89)90249-7 Morganroth, 1975, The biochemical, clinical, and genetic features of type III hyperlipoproteinemia, Ann. Intern. Med., 82, 158, 10.7326/0003-4819-82-2-158 Fredrickson, 1967, Fat transport in lipoproteins—an integrated approach to mechanisms and disorders, N. Engl. J. Med., 276, 34, 10.1056/NEJM196701052760107 Hazzard, 1975, Broad-β disease (type III hyperlipoproteinemia) in a large kindred. Evidence for a monogenic mechanism, Ann. Intern. Med., 82, 141, 10.7326/0003-4819-82-2-141 Fainaru, 1982, Structural and metabolic heterogeneity of β-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia, J. Lipid Res., 23, 702, 10.1016/S0022-2275(20)38102-5 Utermann, 1977, Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man, Nature, 269, 604, 10.1038/269604a0 Utermann, 1980, Genetics of the apolipoprotein E system in man, Am. J. Hum. Genet., 32, 339 Zannis, 1981, Human apolipoprotein E isoprotein subclasses are genetically determined, Am. J. Hum. Genet., 33, 11 Zannis, 1982, Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes, J. Lipid Res., 23, 911, 10.1016/S0022-2275(20)38094-9 Rall, 1982, Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects, Proc. Natl. Acad. Sci. USA, 79, 4696, 10.1073/pnas.79.15.4696 Utermann, 1985, Genetic polymorphism of apolipoprotein E—impact on plasma lipoprotein metabolism, 1 Davignon, 1988, Apolipoprotein E polymorphism and atherosclerosis, Arteriosclerosis, 8, 1, 10.1161/01.ATV.8.1.1 Cooper, 1997, Hepatic uptake of chylomicron remnants, J. Lipid Res., 38, 2173, 10.1016/S0022-2275(20)34932-4 Brown, 1986, A receptor-mediated pathway for cholesterol homeostasis, Science, 232, 34, 10.1126/science.3513311 Brown, 1983, Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic, J. Clin. Invest., 72, 743, 10.1172/JCI111044 Herz, 1988, Surface location and high affinity for calcium of a 500-kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor, EMBO J., 7, 4119, 10.1002/j.1460-2075.1988.tb03306.x Herz, 1994, Functions of the LDL receptor gene family, Ann. NY Acad. Sci., 737, 14, 10.1111/j.1749-6632.1994.tb44298.x Brown, 1991, The low-density lipoprotein receptor-related protein: double agent or decoy?, Curr. Opin. Lipidol., 2, 65, 10.1097/00041433-199104000-00002 Herz, 1995, Lipoprotein and receptor interactions in vivo, Curr. Opin. Lipidol., 6, 97, 10.1097/00041433-199504000-00007 Ji, 1993, Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells, J. Biol. Chem., 268, 10160, 10.1016/S0021-9258(18)82186-X Ji, 1994, Secretion-capture role for apolipoprotein E in remnant lipoprotein metabolism involving cell surface heparan sulfate proteoglycans, J. Biol. Chem., 269, 2764, 10.1016/S0021-9258(17)42009-6 Ji, 1997, Heparan sulfate proteoglycans participate in hepatic lipase- and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins, J. Biol. Chem., 272, 31285, 10.1074/jbc.272.50.31285 Ji, 1995, Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: In vivo role of heparan sulfate proteoglycans, J. Lipid Res., 36, 583, 10.1016/S0022-2275(20)39892-8 Ji, 1998, Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than E4, J. Biol. Chem., 273, 13452, 10.1074/jbc.273.22.13452 Fuki, 1997, The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro, J. Clin. Invest., 100, 1611, 10.1172/JCI119685 Williams, 1997, Cell-surface heparan sulfate proteoglycans: Dynamic molecules mediating ligand catabolism, Curr. Opin. Lipidol., 8, 253, 10.1097/00041433-199710000-00003 Olivecrona, 1993, Lipoprotein lipase and hepatic lipase, Curr. Opin. Lipidol., 4, 187, 10.1097/00041433-199306000-00003 Lalouel, 1992, Lipoprotein lipase and hepatic triglyceride lipase: Molecular and genetic aspects, Curr. Opin. Lipidol., 3, 86, 10.1097/00041433-199204000-00005 Hayden, 1991, Genetic variants affecting human lipoprotein and hepatic lipases, Curr. Opin. Lipidol., 2, 104, 10.1097/00041433-199104000-00008 Brunzell, 1995, Familial lipoprotein lipase deficiency and other causes of the chylomicronemia syndrome, 2, 1913 Rensen, 1996, Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo, J. Biol. Chem., 271, 14791, 10.1074/jbc.271.25.14791 Huang, 1998, Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins, J. Biol. Chem., 273, 17483, 10.1074/jbc.273.28.17483 Huang, 1998, Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia, J. Biol. Chem., 273, 26388, 10.1074/jbc.273.41.26388 Jong, 1997, Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner, Biochem. J., 328, 745, 10.1042/bj3280745 Gómez-Coronado, 1993, Different hydrolytic efficiencies of adipose tissue lipoprotein lipase on very-low-density lipoprotein subfractions separated by heparin-Sepharose chromatography, Biochim. Biophys. Acta., 1167, 70, 10.1016/0005-2760(93)90219-Y .Huang, Y., Ji, Z-S., Brecht, W. J., Rall, S. C., Jr., Taylor, J. M., Mahley, R. W., Overexpression of apolipoprotein E3 in transgenic rabbits causes combined hyperlipidemia by stimulating hepatic very low density lipoprotein (VLDL) production and impairing VLDL lipolysis. Arterioscler. Thromb. Vasc. Biol., In press. Thuren, 1992, Role of apolipoprotein E in hepatic lipase catalyzed hydrolysis of phospholipid in high-density lipoproteins, Biochemistry, 31, 2332, 10.1021/bi00123a018 Thuren, 1991, Hepatic lipase hydrolysis of lipid monolayers. Regulation by apolipoproteins, J. Biol. Chem., 266, 4853, 10.1016/S0021-9258(19)67727-6 Hamilton, 1995, Nascent VLDL assembly occurs in two steps in the endoplasmic reticulum (ER) of hepatocytes, 414 Hamilton, 1994, Apolipoprotein-B-containing plasma lipoproteins in health and in disease, Trends Cardiovasc. Med., 4, 131, 10.1016/1050-1738(94)90065-5 Borén, 1994, Studies on the assembly of apolipoprotein B-100- and B-48-containing very low density lipoproteins in McA-RH7777 cells, J. Biol. Chem., 269, 25879, 10.1016/S0021-9258(18)47328-0 McLeod, 1994, Carboxyl-terminal truncation impairs lipid recruitment by apolipoprotein B100 but does not affect secretion of the truncated apolipoprotein B-containing lipoproteins, J. Biol. Chem., 269, 2852, 10.1016/S0021-9258(17)42021-7 Alexander, 1976, Subcellular localization of B apoprotein of plasma lipoproteins in rat liver, J. Cell Biol., 69, 241, 10.1083/jcb.69.2.241 Dixon, 1993, Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: Information obtained from cultured liver cells, J. Lipid Res., 34, 167, 10.1016/S0022-2275(20)40744-8 Yao, 1994, Synthesis and secretion of hepatic apolipoprotein B-containing lipoproteins, Biochim. Biophys. Acta., 1212, 152, 10.1016/0005-2760(94)90249-6 Raabe, 1999, Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice, J. Clin. Invest., 103, 1287, 10.1172/JCI6576 Gordon, 1994, Secretion of apolipoprotein B-containing lipoproteins from HeLa cells is dependent on expression of the microsomal triglyceride transfer protein and is regulated by lipid availability, Proc. Natl. Acad. Sci. USA, 91, 7628, 10.1073/pnas.91.16.7628 Raabe, 1998, Knockout of the abetalipoproteinemia gene in mice: Reduced lipoprotein secretion in heterozygotes and embryonic lethality in homozygotes, Proc. Natl. Acad. Sci. USA, 95, 8686, 10.1073/pnas.95.15.8686 Wang, 1997, Normal activity of microsomal triglyceride transfer protein is required for the oleate-induced secretion of very low density lipoproteins containing apolipoprotein B from McA-RH7777 cells, J. Biol. Chem., 272, 12272, 10.1074/jbc.272.19.12272 Novikoff, 1977, Fatty liver induced in Zucker “fatty” (ff) rats by a semisynthetic diet rich in sucrose, Proc. Natl. Acad. Sci. USA, 74, 3550, 10.1073/pnas.74.8.3550 Sparks, 1996, Insulin-mediated inhibition of apolipoprotein B secretion requires an intracellular trafficking event and phosphatidylinositol 3-kinase activation: Studies with brefeldin A and wortmannin in primary cultures of rat hepatocytes, Biochem. J., 313, 567, 10.1042/bj3130567 Wang, 1995, Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes, Arterioscler. Thromb. Vasc. Biol., 15, 1481, 10.1161/01.ATV.15.9.1481 van Dijk, 1999, In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE, J. Lipid Res., 40, 336, 10.1016/S0022-2275(20)33374-5 Kuipers, 1997, Impaired secretion of very low density lipoprotein–triglycerides by apolipoprotein E-deficient mouse hepatocytes, J. Clin. Invest., 100, 2915, 10.1172/JCI119841 Salah, 1997, Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort, J. Lipid Res., 38, 904, 10.1016/S0022-2275(20)37215-1 Cohn, 1996, Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects, Arterioscler. Thromb. Vasc. Biol., 16, 149, 10.1161/01.ATV.16.1.149 Millar, 1998, Apo E and apo B100 kinetics in triglyceride-rich lipoproteins and their role in LDL production, Circulation, 98, I-305 Huang, 1996, Hypolipidemic and hyperlipidemic phenotypes in transgenic mice expressing human apolipoprotein E2, J. Biol. Chem., 271, 29146, 10.1074/jbc.271.46.29146 van Vlijmen, 1996, In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158→Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice, J. Biol. Chem., 271, 30595, 10.1074/jbc.271.48.30595 Woollett, 1995, Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse, Proc. Natl. Acad. Sci. USA, 92, 12500, 10.1073/pnas.92.26.12500 Chait, 1977, Type-III hyperlipoproteinæmia (“remnant removal disease”). Insight into the pathogenetic mechanism, Lancet, 1, 1176, 10.1016/S0140-6736(77)92717-9 Chait, 1978, Impaired very low density lipoprotein and triglyceride removal in broad beta disease: Comparison with endogenous hypertriglyceridemia, Metabolism, 27, 1055, 10.1016/0026-0495(78)90151-8 Ehnholm, 1984, Role of apolipoprotein E in the lipolytic conversion of β-very low density lipoproteins to low density lipoproteins in type III hyperlipoproteinemia, Proc. Natl. Acad. Sci. USA, 81, 5566, 10.1073/pnas.81.17.5566 Chung, 1983, Resistance of a very low density lipoprotein subpopulation from familial dysbetalipoproteinemia to in vitro lipolytic conversion to the low density lipoprotein density fraction, J. Lipid Res., 24, 1148, 10.1016/S0022-2275(20)37898-6 Huang, 1997, Genetic factors precipitating type III hyperlipoproteinemia in hypolipidemic transgenic mice expressing human apolipoprotein E2, Arterioscler. Thromb. Vasc. Biol., 17, 2817, 10.1161/01.ATV.17.11.2817 Hazzard, 1981, Genetic transmission of isoapolipoprotein E phenotypes in a large kindred: Relationship to dysbetalipoproteinemia and hyperlipidemia, Metabolism, 30, 79, 10.1016/0026-0495(81)90223-7 Hopkins, 1991, Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction, Arterioscler. Thromb., 11, 1137, 10.1161/01.ATV.11.5.1137 Ma, 1986, Increased mRNA for low density lipoprotein receptor in livers of rabbits treated with 17α-ethinyl estradiol, Proc. Natl. Acad. Sci. USA, 83, 792, 10.1073/pnas.83.3.792 Huang, 1997, Apolipoprotein E2 transgenic rabbits: Modulation of the type III hyperlipoproteinemic phenotype by estrogen and occurrence of spontaneous atherosclerosis, J. Biol. Chem., 272, 22685, 10.1074/jbc.272.36.22685 Ghiselli, 1981, Type III hyperlipoproteinemia associated with apolipoprotein E deficiency, Science, 214, 1239, 10.1126/science.6795720 Kurosaka, 1991, Apolipoprotein E deficiency with a depressed mRNA of normal size, Atherosclerosis, 88, 15, 10.1016/0021-9150(91)90252-X Zhang, 1992, Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E, Science, 258, 468, 10.1126/science.1411543 Plump, 1992, Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells, Cell, 71, 343, 10.1016/0092-8674(92)90362-G Horie, 1992, The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia, J. Biol. Chem., 267, 1962, 10.1016/S0021-9258(18)46040-1 de Knijff, 1991, Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree, J. Clin. Invest., 88, 643, 10.1172/JCI115349 Ji, 1994, Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia, J. Biol. Chem., 269, 13421, 10.1016/S0021-9258(17)36849-7 Wardell, 1987, Apolipoprotein E2-Christchurch (136 Arg→Ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia, J. Clin. Invest., 80, 483, 10.1172/JCI113096 Pocovi, 1996, Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136→Ser) variant in multigenerational pedigree studies, Atherosclerosis, 122, 33, 10.1016/0021-9150(95)06745-0 Feussner, 1994, Apolipoprotein E2Heidelberg (Arg136→Cys), a new variant of apolipoprotein E associated with incomplete dominance of type III hyperlipoproteinemia, Atherosclerosis, 109, 261, 10.1016/0021-9150(94)94042-8 Walden, 1994, Detection of a new apolipoprotein-E mutation in type III hyperlipidemia using deoxyribonucleic acid restriction isotyping, J. Clin. Endocrinol. Metab., 78, 699 Feussner, 1996, Apolipoprotein E2 (Arg-136→Cys), a variant of apolipoprotein E associated with late-onset dominance of type III hyperlipoproteinaemia, Eur. J. Clin. Invest., 26, 13, 10.1046/j.1365-2362.1996.83232.x Richard, 1995, Identification of a new apolipoprotein E variant (E2 Arg142→Leu) in type III hyperlipidemia, Atherosclerosis, 112, 19, 10.1016/0021-9150(94)05393-W Havel, 1983, Atypical familial dysbetalipoproteinemia associated with apolipoprotein phenotype E3/3, J. Clin. Invest., 72, 379, 10.1172/JCI110978 Rall, 1989, Type III hyperlipoproteinemia associated with apolipoprotein E phenotype E3/3. Structure and genetics of an apolipoprotein E3 variant, J. Clin. Invest., 83, 1095, 10.1172/JCI113988 Emi, 1988, Genotyping and sequence analysis of apolipoprotein E isoforms, Genomics, 3, 373, 10.1016/0888-7543(88)90130-9 Lohse, 1991, Apolipoprotein E-4Philadelphia (Glu13→Lys,Arg145→Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia, J. Biol. Chem., 266, 10479, 10.1016/S0021-9258(18)99249-5 Lohse, 1992, Heterozygosity for apolipoprotein E-4Philadelphia (Glu13→Lys, Arg145→Cys) is associated with incomplete dominance of type III hyperlipoproteinemia, J. Biol. Chem., 267, 13642, 10.1016/S0021-9258(18)42261-2 de Villiers, 1997, The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance, Arterioscler. Thromb. Vasc. Biol., 17, 865, 10.1161/01.ATV.17.5.865 Rall, 1983, Identification of a new structural variant of human apolipoprotein E, E2(Lys146→Gln), in a type III hyperlipoproteinemic subject with the E3/2 phenotype, J. Clin. Invest., 72, 1288, 10.1172/JCI111085 Smit, 1990, Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146→gln) variant results in a dominant mode of inheritance, J. Lipid Res., 31, 45, 10.1016/S0022-2275(20)42759-2 de Knijff, 1994, Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2(Lys146→ Gln) allele carriers, J. Clin. Invest., 94, 1252, 10.1172/JCI117443 Mulder, 1994, Triglyceride-rich lipoproteins of subjects heterozygous for apolipoprotein E2(Lys146→Gln) are inefficiently converted to cholesterol-rich lipoproteins, Atherosclerosis, 108, 183, 10.1016/0021-9150(94)90113-9 Mann, 1995, Apolipoprotein E isoforms and rare mutations: Parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia, J. Lipid Res., 36, 517, 10.1016/S0022-2275(20)39885-0 Mann, 1989, Apolipoprotein E-1Harrisburg: a new variant of apolipoprotein E dominantly associated with type III hyperlipoproteinemia, Biochim. Biophys. Acta., 1005, 239, 10.1016/0005-2760(89)90043-X Moriyama, 1992, Apolipoprotein E1 Lys-146→Glu with type III hyperlipoproteinemia, Biochim. Biophys. Acta., 1128, 58, 10.1016/0005-2760(92)90257-V Mann, 1995, Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of apoE-1(Lys146→Glu), J. Clin. Invest., 96, 1100, 10.1172/JCI118096 Hoffer, 1996, Apolipoprotein E1-Hammersmith (Lys146→Asn;Arg147→Trp), due to a dinucleotide substitution, is associated with early manifestation of dominant type III hyperlipoproteinaemia, Atherosclerosis, 124, 183, 10.1016/0021-9150(96)05819-4 Wardell, 1989, Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121–127, J. Biol. Chem., 264, 21205, 10.1016/S0021-9258(19)30067-5 Fazio, 1993, Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma, J. Lipid Res., 34, 447, 10.1016/S0022-2275(20)40736-9 Weisgraber, 1996, Human apolipoprotein E: The Alzheimer's disease connection, FASEB J., 10, 1485, 10.1096/fasebj.10.13.8940294 Weisgraber, 1994, Apolipoprotein E: Structure-function relationships, Adv. Protein Chem., 45, 249, 10.1016/S0065-3233(08)60642-7 Wilson, 1991, Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E, Science, 252, 1817, 10.1126/science.2063194 Dong, 1996, Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia, Nat. Struct. Biol., 3, 718, 10.1038/nsb0896-718 Lalazar, 1988, Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions, J. Biol. Chem., 263, 3542, 10.1016/S0021-9258(18)68957-4 Innerarity, 1984, Normalization of receptor binding of apolipoprotein E2. Evidence for modulation of the binding site conformation, J. Biol. Chem., 259, 7261, 10.1016/S0021-9258(17)39866-6 Fazio, 1993, Type III hyperlipoproteinemic phenotype in transgenic mice expressing dysfunctional apolipoprotein E, J. Clin. Invest., 92, 1497, 10.1172/JCI116728 van den Maagdenberg, 1993, Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia, J. Biol. Chem., 268, 10540, 10.1016/S0021-9258(18)82232-3 van Vlijmen, 1994, Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice, J. Clin. Invest., 93, 1403, 10.1172/JCI117117 Steinmetz, 1989, Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins, Arteriosclerosis, 9, 405, 10.1161/01.ATV.9.3.405 Weisgraber, 1990, Apolipoprotein E distribution among human plasma lipoproteins: Role of the cysteine-arginine interchange at residue 112, J. Lipid Res., 31, 1503, 10.1016/S0022-2275(20)42621-5 Kowal, 1990, Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein, J. Biol. Chem., 265, 10771, 10.1016/S0021-9258(18)87014-4 Mahley, 1999, Type III hyperlipoproteinemia (dysbetalipoproteinemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism Hussain, 1995, Chylomicron metabolism in normal, cholesterol-fed, and Watanabe heritable hyperlipidemic rabbits. Saturation of the sequestration step of the remnant clearance pathway, J. Biol. Chem., 270, 8578, 10.1074/jbc.270.15.8578 Fazio, 1994, Susceptibility to diet-induced atherosclerosis in transgenic mice expressing a dysfunctional human apolipoprotein E(Arg 112,Cys142), Arterioscler. Thromb. Vasc. Biol., 14, 1873, 10.1161/01.ATV.14.11.1873 Mahley, 1985, Atherogenic lipoproteins and coronary artery disease: Concepts derived from recent advances in cellular and molecular biology, Circulation, 72, 943, 10.1161/01.CIR.72.5.943 Mahley, 1985, Lipoproteins of special significance in atherosclerosis. Insights provided by studies of type III hyperlipoproteinemia, Ann. N.Y. Acad. Sci., 454, 209, 10.1111/j.1749-6632.1985.tb11860.x Mahley, 1980, Cholesteryl ester synthesis in macrophages: Stimulation by β-very low density lipoproteins from cholesterol-fed animals of several species, J. Lipid Res., 21, 970, 10.1016/S0022-2275(20)34757-X Koo, 1988, Uptake of cholesterol-rich remnant lipoproteins by human monocyte-derived macrophages is mediated by low density lipoprotein receptors, J. Clin. Invest., 81, 1332, 10.1172/JCI113460 Fujioka, 1998, Multiple processes are involved in the uptake of chylomicron remnants by mouse peritoneal macrophages, J. Lipid Res., 39, 2339, 10.1016/S0022-2275(20)33313-7 Weintraub, 1996, Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over three years, Br. J. Med., 312, 935, 10.1136/bmj.312.7036.935 Weintraub, 1997, Disturbances in dietary fat metabolism and their role in the development of atherosclerosis, Biomed. Pharmacother., 51, 311, 10.1016/S0753-3322(97)88046-8